Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction

Belatacept Conversion in Kidney Transplant Recipients for Prolonged DGF.

(2017) D. Wojciechowski et al.   TRANSPLANTATION

Clinical Outcomes of Kidney Transplant Recipients Switched to Belatacept Based Regimen.

(2017) R. Villicana et al.   TRANSPLANTATION

Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions

(2014) M. Haas et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study

(2013) L. Rostaing et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry

(2012) Anthony Langone et al.   CLINICAL TRANSPLANTATION

Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the TranCept STAY study

(2012) Uwe Heemann et al.   CLINICAL TRANSPLANTATION

Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study

(2012) Josep Grinyo et al.   TRANSPLANT INTERNATIONAL

Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients

(2011) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients

(2011) S. M. Flechner et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)

(2010) A. Durrbach et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients: A Randomized Phase II Study

(2010) L. Rostaing et al.   Clinical Journal of the American Society of Nephrology

Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

(2010) F. Vincenti et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure

(2010) Robert S. Gaston et al.   TRANSPLANTATION